Pros and cons of FDA’s push for nonprescription drugs
Media mention
| 04
March
2026
In this Law360 article, Heidi Gertner, Elizabeth Jungman and Eva Schifini examine the FDA’s renewed push to expand access to nonprescription drugs under Commissioner Martin Makary, including efforts to accelerate prescription-to-OTC switches and the introduction of the additional condition for nonprescription use pathway. They analyze the potential benefits of increased consumer access, affordability, and autonomy, as well as the regulatory, safety, equity, and commercial challenges associated with expanding OTC availability.
The article can be found here.
related_contacts_heading
